LLY Jun 2024 340.000 call
| Previous close | 261.00 |
| Open | 261.00 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 340.00 |
| Expiry date | 2024-06-21 |
| Day's range | 261.00 - 261.00 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Yahoo Finance Video
Weight loss drugs likely to boost apparel stocks: Survey
The market for GLP-1 weight loss drugs such as Wegovy and Ozempic have captured Wall Street's attention. A consumer survey carried out by Stifel Financial (SF) found 15% of respondents currently use a GLP-1 drug while an additional 21% said they would be interested if it were FDA approved with proven results. Stifel Analyst Jim Duffy joins Yahoo Finance to discuss how the uptake of weight loss drugs could prompt a shift in spending trends and the greater impact of GLP-1's across industries. "We do expect that there will be less calories consumed, by the projections of our food & beverage team, get to 4% less calories consumed with this adoption. We do think that there's going to be more apparel spend," Duffy says. "Consumers are losing significant amounts of weight on these drugs, some clinical trials, including one released recently from Mounjaro, speaks to greater than 40% of consumers losing more than 10% of their body weight." Duffy names Lululemon (LULU), Dick's Sporting Goods (DKS) and Levi's (LEVI) as potential winners. Click here to watch the full interview on the Yahoo Finance YouTube page or you can watch this full episode of Yahoo Finance Live here.
ZacksThe Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer
AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.
Motley FoolEli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?
Electronic health records say tirzepatide, the active ingredient in Mounjaro and Zepbound, is better at reducing weight than semaglutide, the active ingredient in Ozempic and Wegovy.
